Using Innovation To Enhance Revelation: SP Genevac EZ-2 Optimizes Screening For Novel Active Antimicrobial Compounds

By Dr. Jayneil Patel, Head of Metabolite Interactions, and Dr. Induka Abeysena, Portfolio Manager, SP Genevac, SP Industries

The development of novel antibiotics that can kill drug-resistant bacteria is essential to maintaining modern medicine standards and mitigating the risk of returning to a pre-antibiotic era. So far, traditional approaches to antibiotic discovery have failed to generate the new drugs needed to treat antibiotic-resistant infections. With a renewed sense of urgency, researchers are once again looking to nature for inspiration to inform the development of new antimicrobial agents.

Discovering and developing genuinely new antibiotics requires challenging science methodologies and is time-consuming and expensive. The start-up company, Bactobio, is not deterred by these obstacles and is dedicated to discovering novel compounds, including antibiotics, from bacteria. Evaporation is a crucial step in their search methodology and has been streamlined using the SP Genevac EZ-2 centrifugal evaporator.